CBD-Infused Gum

CLINICAL THERAPEUTICS

AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market 

nausea

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

covid 19 Testing

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

the Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.